Biological samples study for B-cell lymphoma treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study collects blood and tissue samples from people with B-cell non-Hodgkin lymphoma who are receiving new antibody treatments. The samples help researchers understand how well these treatments work and why they might help some people more than others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with B-cell non-Hodgkin lymphoma.
- You are already enrolled in the main FIL_MAB study and are scheduled to receive a new monoclonal antibody treatment (alone or with other therapies).
- You agree to give blood and tissue samples for research.
- You do not have an active uncontrolled infection, including hepatitis B or C that requires treatment, or HIV.
- You are able to provide written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This study tests an experimental drug for people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has come back or hasn't responded to standard treatments. The goal is to see if the drug is safe and can shrink the cancer.
This study watches how newer monoclonal antibodies (targeted therapies) work for people with B-cell non-Hodgkin lymphoma in real-world Italian clinics. It helps doctors learn more about how these treatments affect patients in everyday care.
This trial tests a new mRNA vaccine designed to help your immune system fight B-cell lymphoma when standard treatments have stopped working or the cancer has returned. The vaccine is given early in testing to see if it is safe and how well it works, while researchers also check how your body responds.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
This early-stage study tests a new medicine (BGB-16673) that targets B-cell cancer cells in people with specific lymphoma or related blood cancers. It aims to see how well the drug can control the cancer and what side effects it causes, especially in Chinese participants.
Hear when a new B-Cell Non-Hodgkin Lymphoma (NHL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.